The FDA on Thursday began easing the process for biosimilar developers to demonstrate interchangeability with their brand-name biologics.
The agency previously required studies to prove …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Lonza Group AG / Key word(s): Annual Results 26-Jan-2024 / 06:50 CET/CEST Release of an ad hoc announcement pursuant to Art. 53 LR The issuer
Revive Therapeutics Ltd. (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT: 31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs
Prior observations that patients suffering spinal cord injuries are prone to develop infections may now have an explanation. Biomarkers of immune activity were depressed for